Note: The following is edited from a press release from Genentech. Read the full press release in its entirety here.
Genentech, a member of the Roche Group, announced on Dec. 9, 2017, new data from the ongoing HEMLIBRA®Â (emicizumab-kxwh) clinical development program were presented at the 59th American Society of Hematology (ASH) Annual Meeting. These data include longer-term results from the pivotal HAVEN 1 and HAVEN 2 studies in people with hemophilia A with inhibitors to factor VIII, showing once-weekly subcutaneous HEMLIBRA prophylaxis demonstrated superior efficacy compared to prior treatment with bypassing agents (BPAs) as prophylaxis or on-demand. These new data from the largest pivotal studies in people with hemophilia A with inhibitors further support HEMLIBRA as an important new treatment option for these adults, adolescents and children.
